Issues with Fertility in Young Women with Breast Cancer
Purpose of Review
There are competing risks and benefits of cancer therapies and fertility preservation in young women with breast cancer. Here we discuss the impact of therapy on fertility, fertility preservation options, and emerging information in fertility issues for the breast cancer patient.
All systemic forms of breast cancer treatment can impact future fertility. Pre-therapy fertility preservation may offer the best opportunity for future fertility. Shared decision making with the individual patient and clinical scenario is important. Early referral to a fertility specialist should be offered to young patients.
We find that fertility preservation options for young women diagnosed with breast cancer are currently available, but potentially under-utilized. We conclude that a multidisciplinary approach is necessary, with discussion of potential risks and benefits of fertility preservation options in the context of the patient’s clinical disease.
KeywordsBreast cancer Fertility preservation IVF Premenopausal breast cancer BRCA
Compliance with Ethical Standards
Conflict of Interest
Nicole Christian and Mary L. Gemignani declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 6.Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7. https://doi.org/10.1016/j.jamcollsurg.2008.12.001.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.NCCN. Pregnancy after cancer. https://www.nccn.org/patients/resources/life_after_cancer/pregnancy.aspx. Accessed 17 Feb 2019.
- 20.•• Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113–28. https://doi.org/10.1007/s10549-014-2914-x. A recent meta-analysis on the impact of multiple types of chemotherapy on chemotherapy-induced amenorrhea. Review and synthesis of available data.CrossRefPubMedGoogle Scholar
- 23.Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69. https://doi.org/10.1200/JCO.2013.54.2258.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. https://doi.org/10.1016/S0140-6736(12)61963-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.•• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164. Long-term follow-up of the SOFT and TEXT trials, demonstrating ovarian suppression with tamoxifen is superior to tamoxifen alone, and exemestane with ovarian suppression is superior to tamoxifen with ovarian suppression.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.•• Saha P, Regan MM, Pagani O, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol. 2017;35(27):3113–22. https://doi.org/10.1200/JCO.2016.72.0946. Young (age < 35 years) premenopausal women with ER+ cancers experience similar symptoms to tamoxifen and ovarian suppression to older women. Approximately 20% of these premenopausal patients stop recommended therapy because of symptoms.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Rosenberg SM, Gelber S, Gelber RD, Krop E, Korde LA, Pagani O, et al. Oncology physicians’ perspectives on practices and barriers to fertility preservation and the feasibility of a prospective study of pregnancy after breast cancer. J Adolesc Young Adult Oncol. 2017;6(3):429–34. https://doi.org/10.1089/jayao.2017.0031.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):mdv374. https://doi.org/10.1093/annonc/mdv374.CrossRefGoogle Scholar
- 33.Armstrong DK, Ω C, Plaxe SC, et al. NCCN Guidelines Version 2.2018 Ovarian Cancer Continue.; 2019. www.nccn.org/patients. Accessed 30 Jan 2019.
- 35.Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7. https://doi.org/10.1200/JCO.2010.31.2462.CrossRefPubMedGoogle Scholar
- 41.Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–7. https://doi.org/10.1007/s10549-014-2891-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Scheffer GJ, Broekmans FJM, Looman CWN, Blankenstein M, Fauser BC, teJong F, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod. 2003;18(4):700–6. http://www.ncbi.nlm.nih.gov/pubmed/12660259. Accessed 30 Jan 2019.CrossRefGoogle Scholar
- 47.•• Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat. 2018;167(3):761–9. https://doi.org/10.1007/s10549-017-4555-3. A cohort/registry study that identifies fertility preservation protocols with hormone stimulation are not associated with worse oncologic outcomes compared to fertility preservation without hormone stimulation.CrossRefPubMedGoogle Scholar
- 48.•• Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027. A meta-analysis of the literature which did not find differences in disease-specific recurrence and survival for patients undergoing ovarian hyperstimulation compared to those who did not for fertility preservation.CrossRefPubMedGoogle Scholar
- 52.•• Derks-Smeets IAP, de Die-Smulders CEM, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat. 2014;145(3):673–81. https://doi.org/10.1007/s10549-014-2951-5. An observational study on the effectiveness of pre-implantation genetic diagnosis for a cohort of BRCA mutation carriers, and results of successful pregnancies.CrossRefPubMedGoogle Scholar